Analyst Thursdays: Benjamin Burnett discusses names and topics on Stifel's 2024 'Key Controversies List'

Reviewing the state of biotech with John Maraganore

As Perlara approaches its 10 yr anniversary, Ethan Perlstein reflects on his entrepreneur's journey and vision for DTC biotech

Xontogeny's Chris Garabedian gives a year-end review and looks ahead to biotech's 2024

Octant Bio's Co-Founder & CEO describes technology advances helping to navigate the biological complexity of multi-modal diseases

Playground Global's $410 million new fund and the firm's philosophy of investing in life sciences

Analyst Thursdays: Evercore ISI Analyst Liisa Bayko takes a deep dive into Vertex's pain data

The present and future of gene editing with Fyodor Urnov

Kicking off Monday (Day 3) of the ASH Annual Meeting with ApexOnco's Jacob Plieth

Mass General's Marcela Maus talks about the latest in cell therapy at #ASH23

Previewing Sunday (Day 2) of the ASH Annual Meeting with ApexOnco's Madeleine Armstrong

Mizuho Senior Analyst Mara Goldstein previews the #ASH23 Annual Meeting

YC Health & Bio Summit: Menlo Ventures' Greg Yap on life sciences, AI, and advice for founders

YC Health & Bio Summit: Y Combinator's Group Partner for Health and Biotech describes how YC works

Mapping autism spectrum disorder protein interactions with the director of UCSF's QBI

William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area

SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

Sofinnova Investments' Jakob Dupont on the private markets in biotech

BMO's Evan Seigerman joins Analyst Thursdays from London

Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays